Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes.

Miners JO, Coulter S, Birkett DJ, Goldstein JA.

Pharmacogenetics. 2000 Apr;10(3):267-70. No abstract available.

PMID:
10803683
2.

Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication.

Ninomiya H, Mamiya K, Matsuo S, Ieiri I, Higuchi S, Tashiro N.

Ther Drug Monit. 2000 Apr;22(2):230-2.

PMID:
10774639
3.

CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates.

Takanashi K, Tainaka H, Kobayashi K, Yasumori T, Hosakawa M, Chiba K.

Pharmacogenetics. 2000 Mar;10(2):95-104.

PMID:
10761997
4.

Effect of the gene dosage of CgammaP2C19 on diazepam metabolism in Chinese subjects.

Qin XP, Xie HG, Wang W, He N, Huang SL, Xu ZH, Ou-Yang DS, Wang YJ, Zhou HH.

Clin Pharmacol Ther. 1999 Dec;66(6):642-6.

PMID:
10613621
5.

High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific islands.

Kaneko A, Lum JK, Yaviong L, Takahashi N, Ishizaki T, Bertilsson L, Kobayakawa T, Björkman A.

Pharmacogenetics. 1999 Oct;9(5):581-90.

PMID:
10591538
6.

Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole.

Ishizaki T, Horai Y.

Aliment Pharmacol Ther. 1999 Aug;13 Suppl 3:27-36. Review.

7.

Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms.

Coller JK, Somogyi AA, Bochner F.

Br J Clin Pharmacol. 1999 Aug;48(2):158-67.

8.

A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin.

Ibeanu GC, Blaisdell J, Ferguson RJ, Ghanayem BI, Brosen K, Benhamou S, Bouchardy C, Wilkinson GR, Dayer P, Goldstein JA.

J Pharmacol Exp Ther. 1999 Aug;290(2):635-40.

9.

CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans.

Furuta T, Ohashi K, Kosuge K, Zhao XJ, Takashima M, Kimura M, Nishimoto M, Hanai H, Kaneko E, Ishizaki T.

Clin Pharmacol Ther. 1999 May;65(5):552-61.

PMID:
10340921
10.

Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele.

Kidd RS, Straughn AB, Meyer MC, Blaisdell J, Goldstein JA, Dalton JT.

Pharmacogenetics. 1999 Feb;9(1):71-80.

PMID:
10208645
11.

Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174.

McCrea JB, Cribb A, Rushmore T, Osborne B, Gillen L, Lo MW, Waldman S, Bjornsson T, Spielberg S, Goldberg MR.

Clin Pharmacol Ther. 1999 Mar;65(3):348-52. No abstract available.

PMID:
10096267
12.
13.

No correlation between side-chain of propranolol oxidation and S-mephenytoin 4'-hydroxylase activity.

Xie HG, Xu ZH, Huang SL, Liu JH, Wu JX, Jiang CH, Zhou HH.

Zhongguo Yao Li Xue Bao. 1997 May;18(3):216-8.

14.

An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians.

Ibeanu GC, Blaisdell J, Ghanayem BI, Beyeler C, Benhamou S, Bouchardy C, Wilkinson GR, Dayer P, Daly AK, Goldstein JA.

Pharmacogenetics. 1998 Apr;8(2):129-35.

PMID:
10022751
15.

Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population.

Yasar U, Eliasson E, Dahl ML, Johansson I, Ingelman-Sundberg M, Sjöqvist F.

Biochem Biophys Res Commun. 1999 Jan 27;254(3):628-31. Erratum in: Biochem Biophys Res Commun 1999 Apr 29;258(1):227.

PMID:
9920790
16.

Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer.

Furuta T, Ohashi K, Kamata T, Takashima M, Kosuge K, Kawasaki T, Hanai H, Kubota T, Ishizaki T, Kaneko E.

Ann Intern Med. 1998 Dec 15;129(12):1027-30.

PMID:
9867757
17.

Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin.

Ibeanu GC, Goldstein JA, Meyer U, Benhamou S, Bouchardy C, Dayer P, Ghanayem BI, Blaisdell J.

J Pharmacol Exp Ther. 1998 Sep;286(3):1490-5.

18.

Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate.

Lillibridge JH, Liang BH, Kerr BM, Webber S, Quart B, Shetty BV, Lee CA.

Drug Metab Dispos. 1998 Jul;26(7):609-16.

19.

The hydroxylation of omeprazole correlates with S-mephenytoin and proguanil metabolism.

Kortunay S, Basci NE, Bozkurt A, Isimer A, Sayal A, Kayaalp SO.

Eur J Clin Pharmacol. 1997;53(3-4):261-4.

PMID:
9476042
20.

A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin.

Ferguson RJ, De Morais SM, Benhamou S, Bouchardy C, Blaisdell J, Ibeanu G, Wilkinson GR, Sarich TC, Wright JM, Dayer P, Goldstein JA.

J Pharmacol Exp Ther. 1998 Jan;284(1):356-61.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk